These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
844 related articles for article (PubMed ID: 19010377)
1. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377 [TBL] [Abstract][Full Text] [Related]
2. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Alderton P; Gross J; Green MD Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226 [TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955 [TBL] [Abstract][Full Text] [Related]
6. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580 [TBL] [Abstract][Full Text] [Related]
7. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. Zhang J; Clark JR; Herman EH; Ferrans VJ J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552 [TBL] [Abstract][Full Text] [Related]
9. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Holm B; Jensen PB; Sehested M Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793 [TBL] [Abstract][Full Text] [Related]
10. Treatment of anthracycline extravasation with dexrazoxane. Langer SW; Sehested M; Jensen PB Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761 [TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Hofland KF; Thougaard AV; Sehested M; Jensen PB Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Tanabe K; Ikegami Y; Ishida R; Andoh T Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204 [TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834 [TBL] [Abstract][Full Text] [Related]
14. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460 [TBL] [Abstract][Full Text] [Related]
15. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Hasinoff BB; Schroeder PE; Patel D Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203 [TBL] [Abstract][Full Text] [Related]
16. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid. De Graff WG; Myers LS; Mitchell JB; Hahn SM Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789 [TBL] [Abstract][Full Text] [Related]
17. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559 [TBL] [Abstract][Full Text] [Related]
18. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Holm B; Sehested M; Jensen PB Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Malisza KL; Hasinoff BB Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623 [TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]